Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia by Luna, A., Pérez-Lamas, L., Boque, C., Giraldo, P., Xicoy, B., Ruiz Nuño, C., Vega, M. Moreno, Alvarez-Larrán, A., Salamanca, A., García-Noblejas, A., Vall-Llovera, F., Villalon, L., De las Heras, N., Ramila, E., Pérez-Encinas, M., Cuevas, B., Perez-Lopez, R., Sanchez-Guijo, F., Jiménez-Velasco, A., Lakhwani, S., Casado, L. Felipe, Rosell, A., Escola, A., Fernández, M. J., Garcia-Hernandez, C., Cervero, C., Mora, E., Sagüés, M., Suarez-Varela, S., Vélez, P., Carrascosa Mastell, P., Bitaube, R. F., Serrano, L., Cortes, M., Vera Goñi, J.A, Steegmann, J. L., de Soria, V. Gomez Garcia, Alonso-Dominguez, J. M., Araujo, M. Colorado, Coll, A. Paz, Hernandez-Boluda, J.C, García-Gutiérrez, V.

Get full text

PB1945 EXPERIENCE OF THE ANDALUSIAN CHRONIC MYELOID LEUKEMIA GROUP (GALMC) IN THE DISCONTINUATION OF THE TYROSINE KINASE INHIBITOR TREATMENT OUTSIDE OF CLINICAL TRIALS by Alarcón‐Payer, C., Puerta Puerta, J.M., Jiménez Morales, A., Ramírez Sánchez, M.J., Montero Cuadrado, M.I., Mata Vázquez, M.I., Ferrer Chaves, C., Anguita Arance, M., Vera Goñi, J.A., García Pérez, M.J., Mellado Gázquez, Á., Moatassim de la Torre, Y., Hermosín Ramos, L., Jurado Chacón, M., López Garrido, P.

Request full text